CR20230069A - Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 - Google Patents

Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2

Info

Publication number
CR20230069A
CR20230069A CR20230069A CR20230069A CR20230069A CR 20230069 A CR20230069 A CR 20230069A CR 20230069 A CR20230069 A CR 20230069A CR 20230069 A CR20230069 A CR 20230069A CR 20230069 A CR20230069 A CR 20230069A
Authority
CR
Costa Rica
Prior art keywords
trem2
agonists
colony
treatment
stimulating factor
Prior art date
Application number
CR20230069A
Other languages
English (en)
Inventor
Berkley A Lynch
Richard Fisher
Judith Dunn
Matthew Brennan
Steven Robinette
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of CR20230069A publication Critical patent/CR20230069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad o trastorno causado por y/o asociado con una disfunción del CSF1R en un paciente humano, el método comprende administrar al paciente que lo necesita una cantidad eficaz de un compuesto que aumenta la actividad del receptor activador expresado en células mieloides 2 (TREM2). En algunas modalidades, el compuesto que aumenta la actividad de TREM2 es un agonista de TREM2. En algunas modalidades, el agonista de TREM2 es un agonista de molécula pequeña de TREM2 o un agonista de anticuerpo de TREM2.
CR20230069A 2020-08-05 2021-08-05 Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 CR20230069A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061315P 2020-08-05 2020-08-05
US202063129852P 2020-12-23 2020-12-23
PCT/US2021/071115 WO2022032293A2 (en) 2020-08-05 2021-08-05 Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists

Publications (1)

Publication Number Publication Date
CR20230069A true CR20230069A (es) 2023-08-16

Family

ID=80117708

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230069A CR20230069A (es) 2020-08-05 2021-08-05 Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2

Country Status (13)

Country Link
US (1) US20220089726A1 (es)
EP (1) EP4192881A2 (es)
JP (1) JP2023536916A (es)
KR (1) KR20230061386A (es)
AU (1) AU2021320553A1 (es)
BR (1) BR112023002093A2 (es)
CA (1) CA3190581A1 (es)
CO (1) CO2023002206A2 (es)
CR (1) CR20230069A (es)
IL (1) IL300327A (es)
MX (1) MX2023001546A (es)
TW (1) TW202218683A (es)
WO (1) WO2022032293A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) * 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279606B (en) * 2014-08-08 2022-08-01 Alector Llc Anti-trem2 antibodies and methods of using them

Also Published As

Publication number Publication date
CA3190581A1 (en) 2022-02-10
IL300327A (en) 2023-04-01
TW202218683A (zh) 2022-05-16
CO2023002206A2 (es) 2023-06-09
WO2022032293A2 (en) 2022-02-10
US20220089726A1 (en) 2022-03-24
AU2021320553A1 (en) 2023-03-02
WO2022032293A3 (en) 2022-03-31
KR20230061386A (ko) 2023-05-08
EP4192881A2 (en) 2023-06-14
JP2023536916A (ja) 2023-08-30
BR112023002093A2 (pt) 2023-04-25
MX2023001546A (es) 2023-05-03

Similar Documents

Publication Publication Date Title
MX2023001546A (es) Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2.
Li et al. Chronic stress exacerbates neuropathic pain via the integration of stress-affect–related information with nociceptive information in the central nucleus of the amygdala
Adam et al. Sleep helps healing.
Spark et al. Hypogonadism, hyperprolactinaemia, and temporal lobe epilepsy in hyposexual men
Bonta et al. 1-Hydroxy-3-amino-pyrrolidone-2 (HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases
RU2010108429A (ru) Регуляторы ммр-9 и их применение
Przeklasa-Muszyńska et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients
KR20160058760A (ko) 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법
Lin et al. Novel therapeutic approach for neurogenic erectile dysfunction: effect of neurotrophic tyrosine kinase receptor type 1 monoclonal antibody
JP2009527497A (ja) 神経原性振戦を調節するための局所麻酔剤の新規適用
Shan et al. Naringenin attenuates fibroblast activation and inflammatory response in a mechanical stretch-induced hypertrophic scar mouse model
JPS59130215A (ja) 錐体外運動障害の軽減法
US7723302B2 (en) Method of treating Parkinson's disease
Kline IV et al. Catechol-O-methyltransferase inhibition alters pain and anxiety-related volitional behaviors through activation of β-adrenergic receptors in the rat
MX2023006397A (es) Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.
Kim et al. Biochemical and functional characterization of alpha-adrenergic receptors in the rabbit vagina
Costa et al. Comparison of analgesia and ataxia degree obtained between three dosages of tramadol in cattle.
Millar et al. Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Shouse et al. Long-lasting effects of feline amygdala kindling on monoamines, seizures and sleep
Ramkissoon et al. G protein-coupled receptors in haematopoietic disruption
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
Ishii et al. Circulating adrenaline released by sympathoadrenal activation elicits acute vasodilatation in the rat masseter muscle
Lacroix et al. The role of ATP in non‐adrenergic sympathetic vascular control of the nasal mucosa in anaesthetized cats and dogs.
Jiang et al. Successful reversal of opioid-induced hyperalgesia and allodynia with duloxetine
Kim et al. Synthetic neurotensin analogues are nontoxic analgesics for the rabbit cornea